These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 32028816)
1. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies. Tang Z; Feng W; Yang Y; Wang Q Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830 [TBL] [Abstract][Full Text] [Related]
3. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models. Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer. Dora CP; Kushwah V; Yadav V; Kuche K; Jain S Mol Pharm; 2024 Jun; 21(6):2699-2712. PubMed ID: 38747900 [TBL] [Abstract][Full Text] [Related]
5. Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. Xu H; Paxton JW; Wu Z Pharm Res; 2015 Jul; 32(7):2428-38. PubMed ID: 25663325 [TBL] [Abstract][Full Text] [Related]
6. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234 [TBL] [Abstract][Full Text] [Related]
7. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. Han NK; Shin DH; Kim JS; Weon KY; Jang CY; Kim JS Int J Nanomedicine; 2016; 11():1413-25. PubMed ID: 27103799 [TBL] [Abstract][Full Text] [Related]
8. Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy. Esim O; Ozkan CK; Sarper M; Savaser A; Ozkan Y Curr Drug Deliv; 2020; 17(7):622-628. PubMed ID: 32394837 [TBL] [Abstract][Full Text] [Related]
9. Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy. Dong S; Guo Y; Duan Y; Li Z; Wang C; Niu L; Wang N; Ma M; Shi Y; Zhang M Anticancer Drugs; 2018 Aug; 29(7):637-645. PubMed ID: 29846247 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo. Yalcin TE; Ilbasmis-Tamer S; Takka S Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141 [TBL] [Abstract][Full Text] [Related]
11. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model. Paolino D; Licciardi M; Celia C; Giammona G; Fresta M; Cavallaro G Eur J Pharm Biopharm; 2012 Sep; 82(1):94-102. PubMed ID: 22705641 [TBL] [Abstract][Full Text] [Related]
12. Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. Jamil A; Aamir Mirza M; Anwer MK; Thakur PS; Alshahrani SM; Alshetaili AS; Telegaonkar S; Panda AK; Iqbal Z Drug Dev Ind Pharm; 2019 May; 45(5):745-753. PubMed ID: 30632800 [TBL] [Abstract][Full Text] [Related]
13. Development of Liposomal Gemcitabine with High Drug Loading Capacity. Tamam H; Park J; Gadalla HH; Masters AR; Abdel-Aleem JA; Abdelrahman SI; Abdelrahman AA; Lyle LT; Yeo Y Mol Pharm; 2019 Jul; 16(7):2858-2871. PubMed ID: 31136710 [TBL] [Abstract][Full Text] [Related]
14. A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy. Ma T; Jiang JL; Qi WX; Chen JY; Xu HP Drug Des Devel Ther; 2022; 16():2395-2406. PubMed ID: 35923931 [TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine. Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611 [TBL] [Abstract][Full Text] [Related]
17. Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma. Wu W; Dai Y; Liu H; Cheng R; Ni Q; Ye T; Cui W Drug Deliv; 2018 Nov; 25(1):1642-1651. PubMed ID: 30799654 [TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes. Zheng Z; Li M; Yang J; Zhou X; Chen Y; Silli EK; Tang J; Gong S; Yuan Y; Zong Y; Kong J; Chen P; Yu L; Luo S; Wang Y; Tan C Int J Biol Macromol; 2024 Oct; 277(Pt 3):134517. PubMed ID: 39111497 [TBL] [Abstract][Full Text] [Related]
19. Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment. Zhang J; Zhang P; Zou Q; Li X; Fu J; Luo Y; Liang X; Jin Y Molecules; 2018 Nov; 23(11):. PubMed ID: 30405089 [TBL] [Abstract][Full Text] [Related]
20. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management. Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]